Death · patients with Guillain‐Barré syndrome
Interferon beta‐1a showed no clear difference in death compared with placebo (low certainty).
1 finding from 1 review
Death or disability after 12 months · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
It is very uncertain whether interferon beta‐1a changes participants with 1 or more serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Improvement in disability grade after 4 weeks · patients with Guillain‐Barré syndrome
1 finding from 1 review
Improvement in disability grade Defined as achievement of a specified degree of improvement · patients with Guillain‐Barré syndrome
It is very uncertain whether brain‐derived neurotrophic factor changes improvement in disability grade Defined as achievement of a… compared with placebo (very low certainty).
1 finding from 1 review
Seizure freedom · patients with drug‐resistant epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Satisfactory seizure control 50% or greater reduction in seizure frequency for drug‐resistant epilepsy · patients with drug‐resistant epilepsy
IVIg showed no clear difference in satisfactory seizure control 50% or greater reduction in seizure… compared with placebo (low certainty).
1 finding from 1 review
All harmful effects · patients with drug‐resistant epilepsy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global assessment · patients with drug‐resistant epilepsy
IVIg may leads to higher global assessment compared with placebo (low certainty).
1 finding from 1 review
Participants able to reduce corticosteroid or IVIg dose by more than 20% · people with CIDP
Methotrexate showed no clear difference in participants able to reduce corticosteroid or IVIg dose by more than… compared with placebo (moderate certainty).
1 finding from 1 review
Change in disability after 26 or more weeks Overall Neuropathy Limitation Scale. Scale from: 0 to 12. · people with CIDP
1 finding from 1 review
Change in disability after 26 or more weeks Amsterdam Linear Disability Scale. Scale from: 0 to 100. · people with CIDP
1 finding from 1 review
Serious adverse events · people with CIDP
Methotrexate showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Change in disability after 26 or more weeks · people with CIDP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants who completed the study and did not restart IVIg therapy after IVIg withdrawal · people with CIDP
Interferon beta‐1a showed no clear difference in participants who completed the study and did not restart IVIg… compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people with CIDP
Interferon beta‐1a showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Change in disability after 4 weeks disability grade change. Scale from: 0 to 10. · patients with Guillain‐Barré syndrome
1 finding from 1 review
Number improved by 1 or more disability grades after 4 weeks · patients with Guillain‐Barré syndrome
IVIg showed no clear difference in number improved by 1 or more disability grades after 4 weeks compared with PE (moderate certainty).
1 finding from 1 review
Dead or disabled after 12 months (48 weeks) · patients with Guillain‐Barré syndrome
IVIg showed no clear difference in dead or disabled after 12 months (48 weeks) compared with PE (low certainty).
1 finding from 1 review
Relapse or treatment‐related fluctuation · patients with Guillain‐Barré syndrome
IVIg showed no clear difference in relapse or treatment‐related fluctuation compared with PE (low certainty).
1 finding from 1 review